Analyser av Kancera

Analysbevakning

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Kancera: Concentrates on cardiovascular diseases - Redeye

Redeye comments on yesterday’s news that Kancera will concentrate its resources on cardiovascular diseases.

Redeye • 13 Nov 09:00

Kancera: Progress according to plan - Redeye

Redeye provides a research update following the Q2 2024 report from Kancera.

Redeye • 26 Aug 07:35

Kancera Q2 2024: Initial comment - Redeye

Redeye provides an initial comment on the Q2 2024 report from Kancera, which showed lower operating costs than we had foreseen.

Redeye • 23 Aug 09:25

Kancera: Positive phase Ib results in KANDOVA - Redeye

Redeye leaves a short comment following Kancera's announcement from earlier this morning regarding clinical advancements in the KANDOVA stud...

Redeye • 11 Jul 09:30

Kancera: Underestimated optionality - Redeye

Redeye initiates coverage of Kancera, a Swedish life science company developing candidates targeting myocardial infarction and ovarian cance...

Redeye • 22 May 07:30